Granulocyte macrophage colony‑stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy

  • Authors:
    • Daisuke Yamada
    • Hirokazu Matsushita
    • Takeshi Azuma
    • Tohru Nakagawa
    • Masayoshi Nagata
    • Yukio Yamada
    • Motofumi Suzuki
    • Tetsuya Fujimura
    • Hiroshi Fukuhara
    • Haruki Kume
    • Yukio Homma
    • Kazuhiro Kakimi
  • View Affiliations

  • Published online on: July 29, 2014     https://doi.org/10.3892/mco.2014.360
  • Pages: 1023-1027
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This prospective study was conducted to identify predictive markers for the response of metastatic renal cell carcinoma (RCC) to tyrosine kinase inhibitors (TKIs). Patients with histologically proven RCC with at least one measurable metastatic lesion were enrolled in this study. Blood samples were collected prior to treatment and the plasma levels of 27 cytokines were measured. Tumor response was assessed 8‑12 weeks after the initiation of TKI treatment. A total of 13 patients (11 men and 2 women) with a median age of 63 years received sunitinib (8 cases), sorafenib (1 case), or axitinib (4 cases). Partial response (PR) was achieved in 5 patients (38%), stable disease (SD) in 4 (30%) and progressive disease (PD) was noted in 4 (30%). The plasma granulocyte macrophage colony‑stimulating factor (GM‑CSF) level in PR cases was significantly higher compared to that in SD or PD cases (P=0.012). Therefore, GM‑CSF may be a predictive biomarker of the response of RCC to TKI treatment, suggesting that TKIs may exert clinical effects not only through suppression of the vascular endothelial growth factor, but also through immune system modulation.
View Figures
View References

Related Articles

Journal Cover

November 2014
Volume 2 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Yamada, D., Matsushita, H., Azuma, T., Nakagawa, T., Nagata, M., Yamada, Y. ... Kakimi, K. (2014). Granulocyte macrophage colony‑stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. Molecular and Clinical Oncology, 2, 1023-1027. https://doi.org/10.3892/mco.2014.360
MLA
Yamada, D., Matsushita, H., Azuma, T., Nakagawa, T., Nagata, M., Yamada, Y., Suzuki, M., Fujimura, T., Fukuhara, H., Kume, H., Homma, Y., Kakimi, K."Granulocyte macrophage colony‑stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy". Molecular and Clinical Oncology 2.6 (2014): 1023-1027.
Chicago
Yamada, D., Matsushita, H., Azuma, T., Nakagawa, T., Nagata, M., Yamada, Y., Suzuki, M., Fujimura, T., Fukuhara, H., Kume, H., Homma, Y., Kakimi, K."Granulocyte macrophage colony‑stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy". Molecular and Clinical Oncology 2, no. 6 (2014): 1023-1027. https://doi.org/10.3892/mco.2014.360